Carnegie acted as joint bookrunner fully underwritten rights issue of approximately NOK 175 million. Targovax is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers.
December 2021.
Healthcare
Rights issue in Targovax ASA (NO) — NOK 175 million
December 2021